In this White Paper we offer an overview on EMA’s guidance for human medicines regarding the detection, management, and prevention of presence of N-nitrosamines, covering its recent update on the scope of September’s 2019 “call for review” to include biological medicinal products.
In it you will find out:
We deliver iRISK™ to our clients. What is iRISK™?
iRISK™ is the next generation Risk Management Platform for the pharmaceutical industry to identify, quantify and prioritise risks, enabling the formulation of the risk mitigation strategy throughout the processes and products lifecycle.